The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
BACKGROUND
Beyond age and comorbidity, functionality can shape the long‐term survival potential of patients with cancer. Accordingly, herein the authors compared mortality and receipt of cancer‐directed surgery according to patient function among older adults with kidney cancer.
METHODS
Using Surveillance, Epidemiology, and End Results (SEER)‐Medicare data from 2000 through 2009, the authors studied...
Clinicians need a simple yet accurate method to predict other-cause mortality to inform medical decision making for men with prostate cancer (PCa).To compare weighted and unweighted Charlson Comorbidity Index scores in predicting long-term, other-cause mortality in men with early-stage PCa.A retrospective cohort study of 1482 men with early-stage PCa diagnosed in 1998–2004 at two Southern California...
BACKGROUND
Men with major comorbidities are at risk for overtreatment of prostate cancer due to uncertainty regarding their life expectancy. We sought to characterize life expectancy and treatment in a population‐based cohort of men with differing ages and comorbidity burdens at diagnosis.
METHODS
We sampled 96,032 men aged ≥66 years with early‐stage prostate cancer who had Gleason scores ≤7 and...
BACKGROUNDThis study sought to compare the effectiveness of aggressive versus nonaggressive treatment in reducing cancer‐specific mortality for older men with early‐stage prostate cancer across differing comorbid disease burdens at diagnosis.
METHODSIn total, the authors sampled 140,553 men aged ≥66 years with early‐stage prostate cancer who were diagnosed between 1991 and 2007 from the Surveillance,...
BACKGROUNDMen with multiple comorbidities are often overtreated for low‐risk prostate cancer, but it is unclear whether they are undertreated for high‐risk cancer, which has appreciable short‐term prostate cancer‐specific mortality. This study characterized the impact of comorbidity on treatment and survival in men with differing tumor risks.
METHODSThe researchers sampled 1482 men with nonmetastatic...
BACKGROUND:Although there is level I evidence demonstrating the superiority of intravesical therapy in patients with bladder cancer, surveillance strategies are primarily founded on expert opinion. The authors examined compliance with surveillance and treatment strategies and the pursuant impact on survival in patients with high‐grade disease.
METHODS:Using linked Surveillance, Epidemiology, and...
BACKGROUND:Men with low‐risk prostate cancer and significant comorbidity are susceptible to overtreatment. The authors sought to compare the impact of comorbidity and age on treatment choice in men with low‐risk disease.
METHODS:The authors sampled 509 men with low‐risk prostate cancer diagnosed at the Greater Los Angeles and Long Beach Veterans Affairs Medical Centers between 1997 and 2004. Rates...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.